Monoclonal Antibody Infusion for Cancer Therapy from Japan
Biotechnologically produced monoclonal antibodies like rituximab for therapeutic infusion in lymphoma treatment. HTS 3002.90.52 includes such immunological products prepared for therapeutic uses. They target specific cancer cells via immune regulation.
Duty Rate — Japan → United States
0%
Rate breakdown
9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Import Tips
• Provide stability data for ambient vs refrigerated shipping to optimize logistics
• Confirm orphan drug status for potential duty exemptions or expedited review
• Document biotech origin to distinguish from chemical synthetics in Chapter 29